Impact of the Daily Use of a Microcrystal Hydroxyapatite Dentifrice on De Novo Plaque Formation and Clinical/Microbiological Parameters of Periodontal Health. A Randomized Trial

PLoS One. 2016 Jul 28;11(7):e0160142. doi: 10.1371/journal.pone.0160142. eCollection 2016.

Abstract

Aim: This 12-week prospective, randomized, double-blind, two-center trial evaluated the impact of a microcrystalline zinc hydroxyapatite (mHA) dentifrice on plaque formation rate (PFR) in chronic periodontitis patients. We hypothesized that mHA precipitates cause delayed plaque development when compared to a fluoridated control (AmF/SnF2), and therefore would improve periodontal health.

Material & methods: At baseline and after 4 and 12 weeks, PFR and other clinical and microbiological parameters were recorded. Seventy periodontitis patients received a mHA or AmF/SnF2 dentifrice as daily oral care without hygiene instructions. Four weeks after baseline, participants received full mouth debridement and continued using the dentifrices for another 8 weeks.

Results: Primary outcome PFR did not change statistically significantly from baseline to weeks 4 and 12, neither in mHA (n = 33; 51.7±17.2% vs. 48.5±16.65% vs. 48.4±19.9%) nor in AmF/SnF2-group (n = 34; 52.3±17.5% vs. 52.5±21.3% vs. 46.1±21.8%). Secondary clinical parameters such as plaque control record, gingival index, bleeding on probing, and pocket probing depth improved, but between-group differences were not statistically significant. Microbiological analyses showed similar slight decreases in colony-forming units in both groups.

Conclusion: In patients with mild-to-moderate periodontitis, periodontal therapy and use of a mHA-or AmF/SnF2 dentifrice without instructions induced comparable improvements in periodontal health but did not significantly reduce the PFR.

Trial registration: ClincalTrials.gov NCT02697539.

Publication types

  • Multicenter Study

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Colony Count, Microbial
  • Crystallization
  • Dental Plaque*
  • Dentifrices / therapeutic use*
  • Double-Blind Method
  • Durapatite / chemistry
  • Durapatite / therapeutic use*
  • Female
  • Humans
  • Male
  • Middle Aged
  • Particle Size
  • Periodontium / microbiology
  • Periodontium / physiology*
  • Young Adult

Substances

  • Dentifrices
  • Durapatite

Associated data

  • ClinicalTrials.gov/NCT02697539

Grants and funding

The authors declare that all study affairs have been exclusively funded by Dr. Kurt Wolff GmbH & CO. KG, Johanneswerkstr. 34 – 36, 33611 Bielefeld, Germany. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.